Fig. 3From: Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in SwedenDeterministic sensitivity analysis of resultsa. aAll variables were tested with an upper and lower bound value of + 25 and − 25%, respectively, except for mortality – delayed therapy with + 20 and − 30%, mortality untreated with + 4 and − 30%, and quality of life with + 20 and − 20%, with upper and lower bound values, respectively. IA, invasive aspergillosis; ICER, incremental cost-effectiveness ratio; IV, intravenous; SEK, Swedish kronaBack to article page